Orizuru Therapeutics

Orizuru Therapeutics is a Japanese biotechnology company specializing in the development of regenerative medicine through induced pluripotent stem cell (iPSC) technology. Established in 2021 as a spinout from the T-CiRA joint research program between Takeda Pharmaceutical and Kyoto University's Center for iPS Cell Research and Application (CiRA), the company focuses on translating advanced academic research into clinical-stage therapies. Their primary mission is to bridge the gap between laboratory innovation and commercial application to address significant unmet medical needs. The company maintains a robust pipeline targeting severe chronic conditions, most notably through its lead assets OZTx-410 for type 1 diabetes and OZTx-556 for refractory heart failure. By utilizing proprietary differentiation methods and large-scale 3D bioreactor manufacturing, Orizuru Therapeutics aims to deliver high-purity cell products that meet pharmaceutical-grade standards. Headquartered at the Shonan Health Innovation Park, the firm continues to advance its clinical programs through strategic partnerships and significant venture capital backing.

To bring hope for better health to the world through the infinite power of science.

• Successful initiation of a physician-led clinical trial for OZTx-410 in 2025
• Spinout from the prestigious T-CiRA collaboration between Takeda and Kyoto University
• Development of proprietary manufacturing processes achieving ~98% purity in cardiomyocytes
• Secured over ¥10 billion in total funding to support clinical development

Sources

• Orizuru Therapeutics Official Website
• Orizuru Therapeutics English Portal